Clazakizumab
Published
Unassigned
New Medicines
Renal transplant chronic active antibody-mediated rejection
Information
New molecular entity
Vitaeris
Vitaeris
Development and Regulatory status
None
Phase III Clinical Trials
Phase III Clinical Trials
Category
Interleukin-6 (IL6) inhibitor produced using yeast cells
Most kidney transplants develop chronic rejection within a decade, and there are currently no effective treatment options [2].
Renal transplant chronic active antibody-mediated rejection
Subcutaneous